| Expression pattern: |
UP |
| Associated gene: |
APPBP2, Snail, E-cadherin, Ki67 |
| Associated microRNA: |
miR-873-5p |
| Biological function: |
Circ_SETD3 promotes gefitinib resistance, proliferation, migration and invasion of gefitinib-resistant NSCLC cells, inhibits apoptosis, and supports tumor progression; circ_SETD3 knockdown improves gefitinib sensitivity in vitro and in vivo. |
| Molecular mechanism: |
Circ_SETD3 acts as a cytoplasmic ceRNA/sponging RNA that binds miR-873-5p and thereby regulates APPBP2 expression, affecting gefitinib sensitivity and malignant progression. |
| Biological pathway or process: |
drug resistance (promotes); proliferation (promotes); migration (promotes); invasion (promotes); apoptosis (inhibits); metastasis (promotes); ceRNA regulation (other) |
| Detected method: |
Q
|
| Validation methods: |
RT-qPCR; Actinomycin D / DRB Stability Assay; Nuclear-Cytoplasmic Fractionation; Clinical Sample Validation; Luciferase Reporter Assay; Transfection; MTT; EdU Staining; Colony Formation Assay; Annexin V/PI Flow Cytometry; Transwell Assay; Western Blot; In Vivo Animal Model; IHC (Immunohistochemistry); Bioinformatics Analysis |
| Clinical significance: |
Circ_SETD3 is upregulated in gefitinib-resistant NSCLC specimens and is proposed as a potential therapeutic target for gefitinib-resistant NSCLC. |
| Description: |
Circ_SETD3 is upregulated in gefitinib-resistant NSCLC tissues and cells. It promotes gefitinib resistance and malignant phenotypes by sponging miR-873-5p and increasing APPBP2 expression, while circ_SETD3 knockdown improves gefitinib sensitivity and suppresses tumor progression in vitro and in vivo. |
| Confidence score: |
0.786 |